Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jan;67(1):19-40.
doi: 10.1007/s11427-022-2340-4. Epub 2023 Sep 15.

Nanomedicine targeting ferroptosis to overcome anticancer therapeutic resistance

Affiliations
Review

Nanomedicine targeting ferroptosis to overcome anticancer therapeutic resistance

Jing Cai et al. Sci China Life Sci. 2024 Jan.

Abstract

A potential reason for the failure of tumor therapies is treatment resistance. Resistance to chemotherapy, radiotherapy, and immunotherapy continues to be a major obstacle in clinic, resulting in tumor recurrence and metastasis. The major mechanisms of therapy resistance are inhibitions of cell deaths, like apoptosis and necrosis, through drug inactivation and excretion, repair of DNA damage, tumor heterogeneity, or changes in tumor microenvironment, etc. Recent studies have shown that ferroptosis play a major role in therapies resistance by inducing phospholipid peroxidation and iron-dependent cell death. Some ferroptosis inducers in combination with clinical treatment techniques have been used to enhance the effect in tumor therapy. Notably, versatile ferroptosis nanoinducers exhibit an extensive range of functions in reversing therapy resistance, including directly triggering ferroptosis and feedback regulation. Herein, we provide a detailed description of the design, mechanism, and therapeutic application of ferroptosis-mediated synergistic tumor therapeutics. We also discuss the prospect and challenge of nanomedicine in tumor therapy resistance by regulating ferroptosis and combination therapy.

Keywords: cancer therapy; ferroptosis; nanoinducers; therapy resistance.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Alvarez, S.W., Sviderskiy, V.O., Terzi, E.M., Papagiannakopoulos, T., Moreira, A.L., Adams, S., Sabatini, D.M., Birsoy, K., and Possemato, R. (2017). NFS1 undergoes positive selection in lung tumours and protects cells from ferroptosis. Nature 551, 639–643. - PubMed - DOI
    1. Brown, C.W., Amante, J.J., Chhoy, P., Elaimy, A.L., Liu, H., Zhu, L.J., Baer, C.E., Dixon, S.J., and Mercurio, A.M. (2019). Prominin2 drives ferroptosis resistance by stimulating iron export. Dev Cell 51, 575–586.e4. - PubMed - DOI
    1. Cao, F., Sang, Y., Liu, C., Bai, F., Zheng, L., Ren, J., and Qu, X. (2022a). Self-adaptive single-atom catalyst boosting selective ferroptosis in tumor cells. ACS Nano 16, 855–868. - PubMed - DOI
    1. Cao, K., Du, Y., Bao, X., Han, M., Su, R., Pang, J., Liu, S., Shi, Z., Yan, F., and Feng, S. (2022b). Glutathione-bioimprinted nanoparticles targeting of N6-methyladenosine FTO demethylase as a strategy against leukemic stem cells. Small 18, 2106558. - DOI
    1. Caramel, J., Ligier, M., and Puisieux, A. (2018). Pleiotropic roles for ZEB1 in cancer. Cancer Res 78, 30–35. - PubMed - DOI

LinkOut - more resources